Kobayashi Jun, Murata Isamu
Faculty of Pharmacy & Pharmaceutical Science, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan.
Ann Intensive Care. 2020 May 20;10(1):61. doi: 10.1186/s13613-020-00681-9.
COVID-19 is an emerging disease of public health concern. While there is no specific recommended treatment for COVID-19, nitric oxide has the potential to be of therapeutic value for managing acute respiratory distress syndrome in patients with COVID-19. However, inhaled nitric oxide has not yet been formally evaluated. Given the extent of the COVID-19 pandemic, and the large numbers of hospitalized patients requiring respiratory support, clinical use of inhaled nitric oxide may become an alternate rescue therapy before extracorporeal membrane oxygenation for the management of acute respiratory distress syndrome in patients with COVID-19.
新型冠状病毒肺炎(COVID-19)是一种引发公众健康关注的新发疾病。虽然目前尚无针对COVID-19的特定推荐治疗方法,但一氧化氮有可能对COVID-19患者急性呼吸窘迫综合征的管理具有治疗价值。然而,吸入一氧化氮尚未经过正式评估。鉴于COVID-19大流行的程度,以及大量需要呼吸支持的住院患者,吸入一氧化氮的临床应用可能会成为在体外膜肺氧合之前用于管理COVID-19患者急性呼吸窘迫综合征的一种替代抢救疗法。